13F-HR filed by QIMING U.S. VENTURES MANAGEMENT, LLC
QIMING U.S. VENTURES MANAGEMENT, LLC filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 8 holding rows worth $109,208,914.
- Accession
- 0001104659-24-023815
- Filer
- CIK 1909617
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 8 entries on the cover page, a total value of $109,208,914 stated on the cover page (in dollars after the unit check, H1), rows summing to $109,208,914 with VALUE read as dollars as filed, 13F file number 028-22101. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ICOSAVAX INC | 45114M109 | COM | 3,510,228 | $55,321,193 | dollars as filed | |
| KORRO BIO INC | 500946108 | COMMON STOCK | 368,085 | $17,642,314 | dollars as filed | |
| Tourmaline Bio Inc | 89157D105 | Common Stock | 641,691 | $16,799,470 | dollars as filed | |
| HILLEVAX INC | 43157M102 | COM | 558,923 | $8,970,714 | dollars as filed | |
| JASPER THERAPEUTICS INC | 471871103 | COM | 8,519,648 | $6,722,002 | dollars as filed | |
| Ventyx Biosciences Inc | 92332V107 | Common Stock | 686,370 | $1,695,334 | dollars as filed | |
| ELEVATION ONCOLOGY INC COM | 28623U101 | Stock | 2,370,142 | $1,272,766 | dollars as filed | |
| KEZAR LIFE SCIENCES INC | 49372L100 | COM | 828,711 | $785,121 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-24-023815 | this filing | 2024-02-14 | acceptance time not in the bulk data set |